Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 50-55-5 | Product Number: R0007
Reserpine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 1G |
$91.00
|
Contact Us | 7 | 19 |
|
| 5G |
$259.00
|
Contact Us | 1 | 16 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | R0007 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__3__3H__4__0N__2O__9 = 608.69 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 50-55-5 |
| Reaxys Registry Number | 102015 |
| PubChem Substance ID | 87575589 |
| SDBS (AIST Spectral DB) | 10992 |
| Merck Index (14) | 8145 |
| MDL Number | MFCD00005091 |
Specifications
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Specific rotation [a]20/D | -172 to -182 deg(C=1, DMF) |
Properties (reference)
| Specific Rotation | 177° (C=1,DMF) |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H370 : Causes damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H350 : May cause cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P307 + P311 : IF exposed: Call a POISON CENTER or doctor/ physician. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | ZG0350000 |
Transport Information:
| HS Number | 2939.79.0000 |
Application
Efflux pump inhibitor
Reserpine can potentially inhibit a diverse range of different efflux pumps, including the resistance nodulation division (RND) family. 1,2)
References
- 1) Identification of natural compounds which inhibit biofilm formation in clinical isolates of Klebsiella pneumoniae.
- 2) Effectiveness of efflux pump inhibitors as biofilm disruptors and resistance breakers in gram-negative (ESKAPEE) bacteria
Application
Reserpine: A Central Nervous System Depressant and an Inhibitor of Multidrug Efflux Pumps in Bacteria
Reserpine is an alkaloid of rauwolfia sharing the yohimbine [Y0002] pentacyclic skeleton. Pharmacological studies have revealed that reserpine is a central nervous system depressant. Reserpine depletes stores of catecholamines (dopamine [A0305], noradrenaline [A0906] and adrenaline [A0173]) and 5-hydroxytryptamine [S0370] by inhibiting their accumulation in many organs, including the brain and adrenal medulla. The depression of the central nervous system results in a decreased heart rate and a lowering of arterial blood pressure.
In addition, some studies have reported that reserpine enhances the in vitro activity of fluoroquinolones, such as norfloxacin [N0817], ciprofloxacin [C2227, C2510] and sparfloxacin [S0840], against strains of Staphylococcus aureus expressing distinct efflux-related multidrug resistance pumps. (The product is for research purpose only.)
In addition, some studies have reported that reserpine enhances the in vitro activity of fluoroquinolones, such as norfloxacin [N0817], ciprofloxacin [C2227, C2510] and sparfloxacin [S0840], against strains of Staphylococcus aureus expressing distinct efflux-related multidrug resistance pumps. (The product is for research purpose only.)
References
- Study of the relationship between the neurotransmitter store and adrenergic nerve block induced by reserpine and guanethidine
- The reserpine receptor (a review)
- How reserpine and chlorpromazine act: the impact of key discoveries on the history of psychopharmacology (a review)
- The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
- A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus
- Reserpine (a review on the description, properties, degradation, metabolism, and analysis of reserpine)
Application
Reagen for myalgia model
References
- Depletion and recovery of neuronal monoamine storage in rats of different ages treated with reserpine
- F. Ponzio, G. Achilli, G. Calderini, P. Ferretti, C. Perego, G. Toffano, S. Algeri, Neurobiol. Aging. 1984, 5, 101.
- Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia
Application
Reagent for pain model
Reference
- Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia
Application
Reagent for schizophrenia model
References
- Electroconvulsive shock: sustained decrease in norepinephrine uptake affinity in a reserpine model of depression
- Prejudices in pharmacology and pharmacotherapy: reserpine as a model for experimental research in depression
- Evaluation of the face validity of reserpine administration as an animal model of depression--Parkinson's disease association
- Antidepressant-like Effect of Tetrahydroisoquinoline Amines in the Animal Model of Depressive Disorder Induced by Repeated Administration of a Low Dose of Reserpine: Behavioral and Neurochemical Studies in the Rat
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.